Table 1 Clinical and molecular characteristics of the patients with AML and samples.

Flow cytometry–based clinical immunophenotyping was performed in fresh red blood cell–depleted bone marrow samples at Helsinki University Hospital, whereas the scRNA-seq profiling was done on the basis of thawed Ficoll-treated and cryopreserved AML cells at the FIMM (Institute for Molecular Medicine Finland) Single-Cell Unit. The blast percentages differ between the two readouts because of different cell isolation protocols and different blast identification approaches. ICD-O, International Classification of Diseases for Oncology.

Patient
sample
Disease
stage
AgeSexscRNA-based
blast (%)
Clinical
morphological
blast (%)
Diagnosis
(ICD-O)
FAB type*Previous
malignancies
or predisposing
conditions
Risk class at
the time of
diagnosis
Potential
driver
mutations
Treatment
history
AML1_DDiagnosis35M6865AML, C92, 9874M2NoLowWT1,
CCND2, and
CEBPA
Cytarabine-
idarubicin,
lenalidomide
AML2_RRefractory68M2640AML C92, 9920NANon-Hodgkin’s
lymphoma
IntermediateDNMT3A, ERG,
U2AF1, and
BCOR
Cytarabine-
idarubicin,
azacytidine
AML3_DDiagnosis70F3570AML C92M1Non-Hodgkin’s
lymphoma
IntermediateNPM1 and TET2Azacitidine
AML3_RRefractory71F5642AML, C92M1Non-Hodgkin’s
lymphoma
IntermediateNPM1, TET2,
and HDAC 1,2,7
Azacitidine-
venetoclax

*FAB, the French-American-British classification.